CD1D

The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy

Retrieved on: 
Tuesday, October 10, 2023
Partnership, Sparx, ASX, SPARX Group, Cell, Therapy, Myeloid-derived suppressor cell, Cytokine release syndrome, Mab, Safety, Hereditary diffuse gastric cancer, Tumor-associated macrophage, GC, MDSC, CD1D, Cancer, Tams, Fatality, Vaccine, Pharmaceutical industry

Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.

Key Points: 
  • Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.
  • Invariant Natural Killer T (iNKT) cells, distinguished by their recognition of lipid antigens via the CD1d molecule, have emerged as potent therapeutic vectors.
  • We profoundly acknowledge CLDN 18.2-iNKT cell therapy as a groundbreaking paradigm in oncological therapeutics."
  • The pathological architecture of tumor development often exposes the CLDN18.2, rendering it accessible to novel treatments such as CAR-iNKT cell therapies.

GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models

Retrieved on: 
Monday, August 7, 2023
CD1D, Lipid, NKT, Autoimmunity, NZW, SAD, SLE, Lupus, Biomarker, Doctor of Philosophy, Nephritis, Proteinuria, Sulfatide, GRI, F1, Patient, Autoimmune disease, Immune system, Lupus nephritis, FASEB, Kidney, Mouse, MAD, NZB, IND, LPC, Natural killer T cell, Conference, Disease, Safety, Inflammation, Vaccine, Pharmaceutical industry

LA JOLLA, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of preclinical data from its GRI-0803 development program at The Autoimmunity Conference hosted by FASEB held July 30-August 3, 2023 in Southbridge, MA.

Key Points: 
  • Dr. Agro commented, “We remain highly encouraged by the animal model data that we observed in connection with GRI-0124 and the second-generation type 2 NKT cell agonist, GRI-0803.
  • The Company has investigated the role of type 2 NKT cells in the spontaneous development of lupus in BWF1 mice.
  • These studies suggest a key role for a type 2 NKT cell-based immune regulatory mechanism in the control of lupus.
  • Based on the data demonstrated to date, GRI Bio plans to evaluate GRI-0803 in a hybrid designed Phase 1 program.

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

Retrieved on: 
Wednesday, June 14, 2023
LAVA, CD1D, Chronic lymphocytic leukemia, PSA, Multiple myeloma, PSMA, Clinical trial, Cancer, Pharmacokinetics, Research, Acute myeloid leukemia, AML, Patient, Knowledge, Therapy, Safety, Bone marrow, Vaccine, Pharmaceutical industry, CLL

UTRECHT, The Netherlands, and PHILADELPHIA, June 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, today announced its decision to rationalize its pipeline and prioritize its lead solid tumor program. The Company will continue to advance LAVA-1207, its Gammabody program designed to target the prostate-specific membrane antigen (PSMA) as well as earlier stage programs. The ongoing clinical trial of LAVA-051 targeting CD1d expressing hematological tumors, including multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML) will be discontinued (NCT04887259).

Key Points: 
  • The Company will continue to advance LAVA-1207, its Gammabody program designed to target the prostate-specific membrane antigen (PSMA) as well as earlier stage programs.
  • The ongoing clinical trial of LAVA-051 targeting CD1d expressing hematological tumors, including multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML) will be discontinued (NCT04887259).
  • The decision to discontinue LAVA-051’s clinical trial follows a recent review of the competitive landscape that has continued to evolve.
  • As a result, we have decided to discontinue this trial and focus our resources on LAVA-1207, partnered programs, and our pipeline.

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, CIN, AACR, CD1D, University, HPV16, RNA, Messenger, E7, Cervical cancer, Patient, Antigen presentation, Nutcracker, HPV, Neoplasm, Cervical intraepithelial neoplasia, Therapy, Tumor microenvironment, Human papillomavirus infection, Prostate cancer, Pharmaceutical industry, Vaccine, DRS

Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).

Key Points: 
  • Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
  • The lead indication for NTX-250 is cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection, which can progress to cervical cancer if left untreated.
  • More than 90 percent of cervical cancer and CIN cases are linked to HPV infection, with HPV16 as the most prevalent high-risk strain.
  • Lawrence Fong and David Oh at the University of California, San Francisco — which mapped shared tumor antigen reactivity using nanoparticle-encapsulated mRNA in prostate cancer patients.

REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Professional Services, Health, Pharmaceutical, Venture Capital, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Mortality, Massachusetts General Hospital, Patient, Cell, AE, Harvard Medical School, Transplant, Limited, Degenerative disease, CD1D, Stomatitis, Associate, Risk, Autoimmunity, Disease, Regulatory T cell, HCT, Nausea, Diarrhea, Survival, Survivor, Society, ASH, HSCT, Immunosuppression, Cancer, Standard of care, Vaccine, Pharmaceutical industry, GVHD

Acute GVHD is characterized as a reaction of donor immune cells against host tissues.

Key Points: 
  • Acute GVHD is characterized as a reaction of donor immune cells against host tissues.
  • RGI-2001, added to standard immunosuppression, is being evaluated for the potential to reduce or prevent aGvHD after HCT.
  • “We are definitely encouraged by the positive results from this study; it also provides a strong foundation to confidently advance our plans for phase 3 study.” said Kenzo Kosuda, CEO of REGiMMUNE.
  • Based on these compelling phase 2b results, REGiMMUNE is strongly considering moving forward with a phase 3 study.

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Saturday, December 10, 2022
Investigational New Drug, NKT, MCRPC, Clinical trial, PD, Cytokine release syndrome, Poster, Safety, CLL, Cancer, Multiple myeloma, CD1D, Pharmacokinetics, Toxic shock syndrome, Exposition, Trial of the century, ASH, Mechanism of action, Monoclonal antibody, AML, CRS, Acute myeloid leukemia, LAVA, Growth, Chronic lymphocytic leukemia, Research, Society, PK, Therapy, MM, COVID-19, Patient, Pharmaceutical industry, Vaccine, EU

The presentation includes initial data from patients receiving LAVA-051 subcutaneously, along with updates on the intravenous dosing-cohorts.

Key Points: 
  • The presentation includes initial data from patients receiving LAVA-051 subcutaneously, along with updates on the intravenous dosing-cohorts.
  • “The LAVA Therapeutics team is committed to transforming treatment for people living with cancer,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.
  • A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling ( NCT05369000 ).
  • LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Society, CD1D, Regulatory T cell, HSCT, Safety, Incidence, ASH, Degenerative disease, CEO, GVHD, Limited, Patient, Cancer, Pharmaceutical industry, Vaccine

This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT.

Key Points: 
  • This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT.
  • The incidence and severity of aGVHD was evaluated in patients treated with RGI-2001 in addition to standard GVHD prevention medications.
  • I am thrilled that the RGI-2001 study results have been selected for oral presentation at the ASH meeting.
  • REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs).

Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron

Retrieved on: 
Monday, October 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, ILT4, Pembrolizumab, Therapy, ILT3, Acute myeloid leukemia, CD1D, White blood cell, AML, LILRB4, LAIR1, NASDAQ, Patient, Drug development, California Institute for Regenerative Medicine, Research, NIH, Twitter, CIRM, Immunotherapy, Regeneron Pharmaceuticals, Cancer, Tumor microenvironment, Leukemia, Company, Lymphatic system, SEMA4A, Leukemia & Lymphoma Society, National Cancer Institute, American Association, National, Association, LLS, Adult, Chronic myelomonocytic leukemia, Heel, BeiGene, CMML, Record, LILRB2, Immunoglobulin G, Regenerative medicine, NCI, Pharmaceutical industry, Vaccine

The Company also entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (Regeneron) to evaluate IO-108 in combination with Regenerons anti-PD-1 therapy, Libtayo (cemiplimab), as part of its ongoing clinical development program.

Key Points: 
  • The Company also entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (Regeneron) to evaluate IO-108 in combination with Regenerons anti-PD-1 therapy, Libtayo (cemiplimab), as part of its ongoing clinical development program.
  • We are incredibly excited to have enrolled the first patient in an expansion cohort of the IO-108 study.
  • The Phase 1 expansion phase includes IO-108 monotherapy cohorts and IO-108 combination cohorts with anti-PD-1 antibodies (pembrolizumab or cemiplimab, depending on tumor types).
  • Under the terms of the agreement, Immune-Onc will sponsor and fund the planned clinical trials and Regeneron will provide cemiplimab (Libtayo).

Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China

Retrieved on: 
Monday, October 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, ILT4, Immunoglobulin G, HLA-G, Pembrolizumab, Therapy, ILT3, Acute myeloid leukemia, CD1D, White blood cell, AML, Tislelizumab, LILRB4, LAIR1, Azacitidine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Drug development, California Institute for Regenerative Medicine, Lymphatic system, CIRM, Research, NIH, Twitter, Â, Immunotherapy, Orphan drug, Cancer, Apolipoprotein E, Food, Tumor microenvironment, Leukemia, National Cancer Institute, SEMA4A, Leukemia & Lymphoma Society, American Association, National, Association, PD-1, LLS, Adult, Chronic myelomonocytic leukemia, CMML, Record, LILRB2, Regenerative medicine, NCI, Vaccine, Pharmaceutical industry, BeiGene

By expanding our reach with BeiGene in China, we have an opportunity to treat a broader array of patients with significant unmet medical needs.

Key Points: 
  • By expanding our reach with BeiGene in China, we have an opportunity to treat a broader array of patients with significant unmet medical needs.
  • Based on strong preclinical and emerging clinical data, we believe there is good synergy between PD-1 and LILRB antagonists for the treatment of solid tumors.
  • Under the terms of the collaboration, Immune-Onc will sponsor and fund the IO-108 and IO-202 clinical trials in China, and BeiGene will provide tislelizumab.
  • The company is actively enrolling a Phase 1 clinical trial in China to evaluate IO-108 in solid tumors.

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Retrieved on: 
Thursday, June 16, 2022
EHA, COVID-19, Safety, Society, Investor relations, American Society of Clinical Oncology, Monoclonal antibody, European Hematology Association, AML, Company, CD1D, Pharmacokinetics, Cancer, Trial of the century, Research, Forward-looking statement, LinkedIn, Chronic lymphocytic leukemia, Congress, Growth, NKT, GLOBE, YouTube, LAVA, MM, Nasdaq, MOA, ASCO, Twitter, Patient, Cytokine release syndrome, Annual general meeting, Therapy, Multiple myeloma, MCRPC, Acute myeloid leukemia, Pharmaceutical industry, Vaccine, CLL

Importantly, the pharmacodynamic determinations gathered from the patients in this early clinical study reflect the mechanism of action of LAVA-051.

Key Points: 
  • Importantly, the pharmacodynamic determinations gathered from the patients in this early clinical study reflect the mechanism of action of LAVA-051.
  • Based on extensive preclinical work, we believe our approach has the potential to lead to substantial improvement for patients.
  • LAVA-051, the Companys lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study ( NCT04887259 ).
  • A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling ( NCT05369000 ).